{"result_id": "318037", "URL": "https://www.trialsitenews.com/a/covid-19-vaccine-developed-in-spain-authorized-by-european-medicines-agency-f268d5f9", "timestamp": "2023-04-25 17:44:00 CEST+0200", "meta": {"description": "Transparent coverage of clinical research", "lang": "en", "keywords": "", "favicon": "", "canonical": "https://www.trialsitenews.com/a/covid-19-vaccine-developed-in-spain-authorized-by-european-medicines-agency-f268d5f9", "encoding": "utf-8"}, "image": null, "domain": "www.trialsitenews.com", "title": "COVID-19 Vaccine Developed in Spain Authorized by European Medicines Agency", "cleaned_text": "", "opengraph": {"image": "https://imagedelivery.net/WEWiZyGwyq-Q4qn_WluYYg/95bcbb33-bc16-4c1d-e038-42f418577000/public", "description": "Yet another COVID-19 vaccine was recently authorized in Europe. This time, a COVID-19 vaccine developed in Spain and plagued by delays has been recommended for authorization by the European Medicines Agency (EMA). Bimervax (previously COVID-19 Vaccine HIPRA). It is now authorized in Europe as a booster in people aged 16 years and above who have been vaccinated with an mRNA COVID-19 vaccine.\nDeveloped by HIPRA Human Health S.L.U., Bimervax contains a protein produced in the laboratory that consists of part of the SARS-CoV-2 spike protein from the Alpha and Beta virus variants."}, "tags": [], "tweets": [], "movies": [], "links": [], "authors": [], "publish_date": null}